Novo Nordisk India Plans To Triple Staff Size In Four Years
This article was originally published in PharmAsia News
Novo Nordisk India plans to expand its business in India by tripling its staff in four years and strengthening partnerships with Indian drug makers. The firm says the move is part of an effort to build its diabetes business. Novo Nordisk has joined with India's Torrent Pharma to provide strength in discovering and manufacturing new diabetes drugs. The firm now has more than 600 employees in India, but it wants to be a leader in the insulin business in a country that is considered the biggest for diabetes care. (Click here for more
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.